<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>News</title>
	<atom:link href="https://www.worldpharmatoday.com/news/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Mon, 20 Jul 2026 13:22:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>News</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Samsung Biologics Launches CHF 1.46B Acquisition of PolyPeptide to Scale Peptide Capabilities</title>
		<link>https://www.worldpharmatoday.com/news/samsung-biologics-launches-chf-1-46b-acquisition-of-polypeptide-to-scale-peptide-capabilities/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 20 Jul 2026 13:22:51 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Acquisition]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/samsung-biologics-launches-chf-1-46b-acquisition-of-polypeptide-to-scale-peptide-capabilities/</guid>

					<description><![CDATA[<p>The global biopharmaceutical contract manufacturing sector is undergoing a rapid transition toward complex modalities as drug developers prioritize specialized treatments for metabolic and chronic conditions. In a major move to consolidate its position within the high-growth peptide market, Samsung Biologics has announced an all-cash public tender offer to acquire 100% of PolyPeptide Group AG. Valued [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/samsung-biologics-launches-chf-1-46b-acquisition-of-polypeptide-to-scale-peptide-capabilities/">Samsung Biologics Launches CHF 1.46B Acquisition of PolyPeptide to Scale Peptide Capabilities</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>How Pharmaceutical Manufacturers Validate GMP Cleaning Protocols: ATP Bioluminescence Testing for Contamination Control</title>
		<link>https://www.worldpharmatoday.com/news/how-pharmaceutical-manufacturers-validate-gmp-cleaning-protocols-atp-bioluminescence-testing-for-contamination-control/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 20 Jul 2026 07:40:07 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/how-pharmaceutical-manufacturers-validate-gmp-cleaning-protocols-atp-bioluminescence-testing-for-contamination-control/</guid>

					<description><![CDATA[<p>You know how quickly a single overlooked residue can turn into a recalled batch or a Form 483 citation. Good manufacturing practice cleaning validation exists precisely because visual inspection alone cannot catch invisible protein or chemical carryover between production runs. Adenosine triphosphate (ATP) bioluminescence testing is one of the fastest ways to verify organic residue [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/how-pharmaceutical-manufacturers-validate-gmp-cleaning-protocols-atp-bioluminescence-testing-for-contamination-control/">How Pharmaceutical Manufacturers Validate GMP Cleaning Protocols: ATP Bioluminescence Testing for Contamination Control</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Why Specialty Pharmacy Accreditation Matters: Standards for Pharmaceutical Distribution and Patient Outcomes</title>
		<link>https://www.worldpharmatoday.com/news/why-specialty-pharmacy-accreditation-matters-standards-for-pharmaceutical-distribution-and-patient-outcomes/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 20 Jul 2026 07:25:08 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/why-specialty-pharmacy-accreditation-matters-standards-for-pharmaceutical-distribution-and-patient-outcomes/</guid>

					<description><![CDATA[<p>In This Article This article contains: What Is a Specialty Pharmacy and Why Does It Need Specific Standards? The Core Pillars of Pharmacy Accreditation An Overview of Leading Accreditation Bodies The Next Frontier: Why AI in Health Care Requires a New Level of Accreditation How to Choose the Right Accreditation Partner for Your Needs Frequently [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/why-specialty-pharmacy-accreditation-matters-standards-for-pharmaceutical-distribution-and-patient-outcomes/">Why Specialty Pharmacy Accreditation Matters: Standards for Pharmaceutical Distribution and Patient Outcomes</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Strategic Alliance Boosts Nutraceutical Innovation and Trade</title>
		<link>https://www.worldpharmatoday.com/news/strategic-alliance-boosts-nutraceutical-innovation-and-trade/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 13:09:24 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Nutraceutical]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/strategic-alliance-boosts-nutraceutical-innovation-and-trade/</guid>

					<description><![CDATA[<p>The Organic &#38; Natural Health Association has officially entered into a strategic partnership with the Shellac &#38; Forest Products Export Promotion Council (SHEFEXIL) to bolster scientific collaboration and trade within the sector. This agreement, finalized this week, represents the first formal collaboration between the Indian export body and a trade association based in the United [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/strategic-alliance-boosts-nutraceutical-innovation-and-trade/">Strategic Alliance Boosts Nutraceutical Innovation and Trade</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Australia Reviews PBS Pricing Framework Amid Industry Dispute Over Benchmarks</title>
		<link>https://www.worldpharmatoday.com/news/australia-reviews-pbs-pricing-framework-amid-industry-dispute-over-benchmarks/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 11:30:51 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/australia-reviews-pbs-pricing-framework-amid-industry-dispute-over-benchmarks/</guid>

					<description><![CDATA[<p>The Australian government is currently navigating a significant period of reassessment regarding its national drug reimbursement model, as tensions between global pharmaceutical manufacturers and health regulators reach a critical juncture. At the center of this dispute is the Pharmaceutical Benefits Scheme (PBS), a system that has long served as the primary mechanism for ensuring affordable [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/australia-reviews-pbs-pricing-framework-amid-industry-dispute-over-benchmarks/">Australia Reviews PBS Pricing Framework Amid Industry Dispute Over Benchmarks</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>SK Telecom and SK Biopharmaceuticals Identify Lead Compounds for Cancer Treatment via AI</title>
		<link>https://www.worldpharmatoday.com/news/sk-telecom-and-sk-biopharmaceuticals-identify-lead-compounds-for-cancer-treatment-via-ai/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 15 Jul 2026 13:29:18 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/sk-telecom-and-sk-biopharmaceuticals-identify-lead-compounds-for-cancer-treatment-via-ai/</guid>

					<description><![CDATA[<p>SK Telecom and SK Biopharmaceuticals have announced the successful identification of early lead compounds designed for the development of targeted therapies for intractable cancers. By leveraging AI Drug Discovery, the joint research team discovered two specific substances capable of binding to ROR1, a protein found on the surface of malignant cells. A major highlight of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/sk-telecom-and-sk-biopharmaceuticals-identify-lead-compounds-for-cancer-treatment-via-ai/">SK Telecom and SK Biopharmaceuticals Identify Lead Compounds for Cancer Treatment via AI</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Senate Investigates Foreign Control and Ownership within the Pharmaceutical Sector</title>
		<link>https://www.worldpharmatoday.com/news/senate-investigates-foreign-control-and-ownership-within-the-pharmaceutical-sector/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 14 Jul 2026 13:41:05 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/senate-investigates-foreign-control-and-ownership-within-the-pharmaceutical-sector/</guid>

					<description><![CDATA[<p>The Senate Special Committee on Aging is preparing to conduct a hearing titled &#8220;Behind The Label: Focusing On Foreign Ownership And Control In America&#8217;s Drug Supply Chain.&#8221; Scheduled for Wednesday, July 15, the session arrives as the industry faces significant pressure from impending tariffs on imported medications. Senator Rick Scott, serving as the committee chair, [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/senate-investigates-foreign-control-and-ownership-within-the-pharmaceutical-sector/">Senate Investigates Foreign Control and Ownership within the Pharmaceutical Sector</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Germany to Double Mandatory Drug Rebates to 15.5 Percent</title>
		<link>https://www.worldpharmatoday.com/news/germany-to-double-mandatory-drug-rebates-to-15-5-percent/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 14 Jul 2026 13:37:36 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pricing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/germany-to-double-mandatory-drug-rebates-to-15-5-percent/</guid>

					<description><![CDATA[<p>As European nations seek to stabilize their national health systems, the resulting regulatory changes are prompting a reassessment of market priority and supply chain reshoring. In a significant escalation of this trend, German lawmakers have finalized a sweeping health insurance reform package that more than doubles the mandatory drug rebates that manufacturers must pay on [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/germany-to-double-mandatory-drug-rebates-to-15-5-percent/">Germany to Double Mandatory Drug Rebates to 15.5 Percent</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>AstraZeneca Secures Global Rights for Zegfrovy Lung Cancer Therapy</title>
		<link>https://www.worldpharmatoday.com/news/astrazeneca-secures-global-rights-for-zegfrovy-lung-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 14 Jul 2026 13:30:33 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/astrazeneca-secures-global-rights-for-zegfrovy-lung-cancer-therapy/</guid>

					<description><![CDATA[<p>AstraZeneca has expanded its oncology pipeline through a $1.5 billion agreement with Dizal Pharma, securing the Zegfrovy global rights. This oral lung cancer therapy, also known as sunvozertinib, is an irreversible EGFR inhibitor. Currently, sunvozertinib is approved in China and the United States as a second-line treatment for adults with locally advanced or metastatic non-small [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/astrazeneca-secures-global-rights-for-zegfrovy-lung-cancer-therapy/">AstraZeneca Secures Global Rights for Zegfrovy Lung Cancer Therapy</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>FDA Proposes New Rule for Drug Manufacturing Registration</title>
		<link>https://www.worldpharmatoday.com/news/fda-proposes-new-rule-for-drug-manufacturing-registration/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 14 Jul 2026 10:11:26 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[FDA]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/fda-proposes-new-rule-for-drug-manufacturing-registration/</guid>

					<description><![CDATA[<p>The modernization of regulatory frameworks is becoming essential to support the pharmaceutical industry’s transition toward advanced production models and to ensure the resilience of global supply chains. As innovative manufacturing technologies emerge, traditional oversight mechanisms must evolve to maintain safety standards while reducing unnecessary complexity for producers. In a significant move to align regulations with [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/fda-proposes-new-rule-for-drug-manufacturing-registration/">FDA Proposes New Rule for Drug Manufacturing Registration</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
